-
Je něco špatně v tomto záznamu ?
Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis
S. Witt, E. Krauss, MAN. Barbero, V. Müller, P. Bonniaud, C. Vancheri, AU. Wells, M. Vasakova, A. Pesci, W. Klepetko, W. Seeger, B. Crestani, R. Leidl, R. Holle, L. Schwarzkopf, A. Guenther,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, časopisecké články
NLK
BioMedCentral
od 2000-04-01
BioMedCentral Open Access
od 2000
Directory of Open Access Journals
od 2000
Free Medical Journals
od 2000
PubMed Central
od 2000
Europe PubMed Central
od 2000
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2000-01-01
Open Access Digital Library
od 2000-06-01
Open Access Digital Library
od 2000-01-01
Medline Complete (EBSCOhost)
od 2000-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2000
Springer Nature OA/Free Journals
od 2000-04-01
- MeSH
- idiopatická plicní fibróza diagnóza epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- longitudinální studie MeSH
- následné studie MeSH
- průřezové studie MeSH
- průzkumy a dotazníky normy MeSH
- psychometrie MeSH
- reprodukovatelnost výsledků MeSH
- senioři MeSH
- zdravotní stav * MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a rare disease with a median survival of 3-5 years after diagnosis with limited treatment options. The aim of this study is to assess the psychometric characteristics of the Short Form 36 Health Status Questionnaire (SF-36) in IPF and to provide disease specific minimally important differences (MID). METHODS: Data source was the European IPF Registry (eurIPFreg). The psychometric properties of the SF-36 version 2 were evaluated based on objective clinical measures as well as subjective perception. We analysed acceptance, feasibility, discrimination ability, construct and criterion validity, responsiveness and test-retest-reliability. MIDs were estimated via distribution and anchor-based approaches. RESULTS: The study population included 258 individuals (73.3% male; mean age 67.3 years, SD 10.7). Of them 75.2% (194 individuals) had no missing item. The distribution of several items was skewed, although floor effect was acceptable. Physical component score (PCS) correlated significantly and moderately with several anchors, whereas the correlations of mental component score (MCS) and anchors were only small. The tests showed mainly significant lower HRQL in individuals with long-term oxygen therapy. Analyses in stable individuals did not show significant changes of HRQL except for one dimension and anchor. Individuals with relevant changes of the health status based on the anchors had significant changes in all SF-36 dimensions and summary scales except for the dimension PAIN. PCS and MCS had mean MIDs of five and six, respectively. Mean MIDs of the dimensions ranged from seven to 21. CONCLUSION: It seems that the SF-36 is a valid instrument to measure HRQL in IPF and so can be used in RCTs or individual monitoring of disease. Nevertheless, the additional evaluation of longitudinal aspects and MIDs can be recommended to further analyse these factors. Our findings have a great potential impact on the evaluation of IPF patients. TRIAL REGISTRATION: The eurIPFreg and eurIPFbank are listed in https://clinicaltrials.gov ( NCT02951416 ).
European IPF Registry and Biobank Giessen Germany Hospital Clinico San Carlos Madrid Spain
European IPF Registry and Biobank Giessen Germany Ospedale San Gerardo Monza Italy
European IPF Registry and Biobank Giessen Marburg Germany
European IPF Registry and Biobank Hôpital Bichat Service de Pneumologie Paris France
Helmholtz Zentrum München German Research Center for Environmental Health Neuherberg Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19027760
- 003
- CZ-PrNML
- 005
- 20190822102501.0
- 007
- ta
- 008
- 190813s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12931-019-1010-5 $2 doi
- 035 __
- $a (PubMed)30823880
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Witt, Sabine $u Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Institute of Health Economics and Health Care Management, Member of the German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Neuherberg, Germany. sabine.witt@helmholtz-muenchen.de.
- 245 10
- $a Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis / $c S. Witt, E. Krauss, MAN. Barbero, V. Müller, P. Bonniaud, C. Vancheri, AU. Wells, M. Vasakova, A. Pesci, W. Klepetko, W. Seeger, B. Crestani, R. Leidl, R. Holle, L. Schwarzkopf, A. Guenther,
- 520 9_
- $a BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a rare disease with a median survival of 3-5 years after diagnosis with limited treatment options. The aim of this study is to assess the psychometric characteristics of the Short Form 36 Health Status Questionnaire (SF-36) in IPF and to provide disease specific minimally important differences (MID). METHODS: Data source was the European IPF Registry (eurIPFreg). The psychometric properties of the SF-36 version 2 were evaluated based on objective clinical measures as well as subjective perception. We analysed acceptance, feasibility, discrimination ability, construct and criterion validity, responsiveness and test-retest-reliability. MIDs were estimated via distribution and anchor-based approaches. RESULTS: The study population included 258 individuals (73.3% male; mean age 67.3 years, SD 10.7). Of them 75.2% (194 individuals) had no missing item. The distribution of several items was skewed, although floor effect was acceptable. Physical component score (PCS) correlated significantly and moderately with several anchors, whereas the correlations of mental component score (MCS) and anchors were only small. The tests showed mainly significant lower HRQL in individuals with long-term oxygen therapy. Analyses in stable individuals did not show significant changes of HRQL except for one dimension and anchor. Individuals with relevant changes of the health status based on the anchors had significant changes in all SF-36 dimensions and summary scales except for the dimension PAIN. PCS and MCS had mean MIDs of five and six, respectively. Mean MIDs of the dimensions ranged from seven to 21. CONCLUSION: It seems that the SF-36 is a valid instrument to measure HRQL in IPF and so can be used in RCTs or individual monitoring of disease. Nevertheless, the additional evaluation of longitudinal aspects and MIDs can be recommended to further analyse these factors. Our findings have a great potential impact on the evaluation of IPF patients. TRIAL REGISTRATION: The eurIPFreg and eurIPFbank are listed in https://clinicaltrials.gov ( NCT02951416 ).
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 12
- $a zdravotní stav $7 D006304
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a idiopatická plicní fibróza $x diagnóza $x epidemiologie $7 D054990
- 650 _2
- $a longitudinální studie $7 D008137
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a psychometrie $7 D011594
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a průzkumy a dotazníky $x normy $7 D011795
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Krauss, Ekaterina $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Marburg, Germany.
- 700 1_
- $a Barbero, María Asunción Nieto $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Hospital Clinico San Carlos, Madrid, Spain.
- 700 1_
- $a Müller, Veronika $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Department of Pulmonology, Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Bonniaud, Philippe $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Reference Center for Rare Pulmonary Diseases, Centre Hospitalier Universitaire Dijon-Bourgogne, INSERMU1231, Université Bourgogne/Franche-Comté, Dijon, France.
- 700 1_
- $a Vancheri, Carlo $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Department of Clinical and Molecular Biomedicine, Università degli Studi di Catania, Catania, Italy.
- 700 1_
- $a Wells, Athol U $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK.
- 700 1_
- $a Vasakova, Martina $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. First Faculty of Medicine, Thomayer University Hospital Prague, Prague, Czech Republic.
- 700 1_
- $a Pesci, Alberto $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Ospedale San Gerardo, Monza, Italy.
- 700 1_
- $a Klepetko, Walter $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Department of Thoracic Surgery, Vienna University Hospital, Vienna, Austria.
- 700 1_
- $a Seeger, Werner $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Marburg, Germany. Cardio-Pulmonary Institute (CPI), EXC 2026, Project ID: 390649896, Justus-Liebig University Giessen , Giessen, Germany.
- 700 1_
- $a Crestani, Bruno $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Institut National de la Santé et de la Recherche Médicale (INSERM 700), Hôpital Bichat, Service de Pneumologie, Paris, France.
- 700 1_
- $a Leidl, Reiner $u Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Institute of Health Economics and Health Care Management, Member of the German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Neuherberg, Germany. Ludwig-Maximilians-University, Munich Center of Health Sciences, Munich, Germany.
- 700 1_
- $a Holle, Rolf $u Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Institute of Health Economics and Health Care Management, Member of the German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Neuherberg, Germany.
- 700 1_
- $a Schwarzkopf, Larissa $u Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Institute of Health Economics and Health Care Management, Member of the German Center for Lung Research (DZL), Comprehensive Pneumology Center Munich (CPC-M), Neuherberg, Germany.
- 700 1_
- $a Guenther, Andreas $u European IPF Registry & Biobank (eurIPFreg/bank), Giessen, Germany. Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Marburg, Germany. Cardio-Pulmonary Institute (CPI), EXC 2026, Project ID: 390649896, Justus-Liebig University Giessen , Giessen, Germany. AGAPLESION Lung Clinic Waldhof-Elgershausen, Greifenstein, Germany.
- 773 0_
- $w MED00006600 $t Respiratory research $x 1465-993X $g Roč. 20, č. 1 (2019), s. 47
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30823880 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190813 $b ABA008
- 991 __
- $a 20190822102740 $b ABA008
- 999 __
- $a ok $b bmc $g 1432909 $s 1066220
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 20 $c 1 $d 47 $e 20190301 $i 1465-993X $m Respiratory research $n Respir Res $x MED00006600
- LZP __
- $a Pubmed-20190813
